VASTox expands pipeline with DanioLabs, Dextra buyout

The U.K.'s VASTox has simultaneously acquired DanioLabs and Dextra Laboratories for a collective £16.5 million. The deal gives VASTox two clinical and two pre-clinical programs in neurological and ophthalmic diseases. VASTox also touted its acquisition of new expertise in zebrafish chemical genomics and carbohydrate chemistry through the acquisition of two laboratories in Cambridge and Reading. DanioLabs claimed the bulk of the money, with a price of £15 million.

- see the release for more information (.pdf)

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.